Marco Campione
President / CEO
BE
Blue Earth Diagnostics, Inc. (U.S.)
Blue Earth Diagnostics develops molecular imaging technologies that enhance the clinical management of recurrent prostate cancer by providing precise diagnostic information. Their products enable healthcare professionals to make informed treatment decisions, addressing the critical need for reliable imaging in cancer care.
- Biotechnology
- Healthcare Technology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Accurate detection and localization of recurrent prostate cancer is challenging, often requiring invasive procedures or lacking the sensitivity to identify small or distant metastases. This can lead to delayed or inappropriate treatment decisions, impacting patient outcomes and quality of life.
Solution
Blue Earth Diagnostics develops and commercializes PET imaging agents that enable high-resolution visualization of prostate-specific membrane antigen (PSMA) expression, a biomarker for prostate cancer. These agents, when used with PET/CT imaging, provide clinicians with detailed information about the location and extent of recurrent or metastatic disease. By improving the accuracy of staging and restaging, Blue Earth Diagnostics' products help guide treatment planning, monitor therapy response, and potentially improve patient outcomes. The company's focus is on addressing unmet clinical needs in prostate cancer management through innovative molecular imaging technologies.
Target Audience
The primary target audience includes urologists, radiation oncologists, and nuclear medicine physicians involved in the diagnosis and management of prostate cancer.
Features
- PSMA-targeted PET imaging agents for enhanced detection of prostate cancer recurrence
- High-resolution imaging capabilities for precise localization of disease
- Improved sensitivity compared to conventional imaging modalities
- Facilitates informed treatment decisions based on accurate staging and restaging
- Non-invasive alternative to surgical biopsy for assessing disease extent